Head-to-head · WeighScore
He & She MD vs WeightRx
The verdict
WeightRx takes it — 72.1/100 to 71.5/100, but only just.
WeightRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. WeightRx is a telehealth provider publishing compounded semaglutide at $250/mo and compounded tirzepatide at $83/mo. He & She MD is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | He & She MD | WeightRx |
|---|---|---|
| WeighScore | 71.5/100 | 72.1/100 |
| Grade | C | C |
| Scorecard rank | #91 | #85 |
| Semaglutide | $139/mo (starting dose, promotional rate, compounded) | $250/mo (compounded) |
| Tirzepatide | $199/mo (starting dose, compounded) | $83/mo (term not published, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #91 · C
Strengths
- Transparent intro pricing: injectable GLP-1 from $139/month, oral from $199, microdose from $99
- Compounded semaglutide and tirzepatide (injectable or oral) plus brand access to Ozempic, Wegovy, Zepbound
- Only charged if medication is prescribed; no hidden fees
- Free expedited shipping and unlimited board-certified clinician access
- GLP-1 coaching, nutrition guidance, and in-app progress tracking
Where it loses points
- Compounded GLP-1s are not FDA-approved finished products (per the site FDA disclaimer)
- Does not ship to Louisiana or to PO boxes
- Introductory pricing rises after the 6-month (or 3-month microdose) plan
- Cash-pay model — insurance billing not indicated
Graded #85 · C
Strengths
- The tirzepatide figure is published up front, and it is genuinely low against the field
- Both molecules are offered
- No membership charge is advertised alongside the medication rate
Where it loses points
- The $83 monthly rate is advertised as '$83/month ($997/year)', which is twelve months of it — no month-to-month rate is separately published, and the terms state that a rate is locked for its full term
- Both product pages linked from the homepage return 404, so the plan terms cannot be read before intake
- Six- and twelve-month plans are non-refundable, and eligible refunds carry a 5% processing fee
- No dose strength is published anywhere, so what the $83 buys is not stated
- The named operator is Twist G Marketing, LLC rather than a clinical entity, and the terms carry a binding arbitration and class-action waiver
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.